SCHEMBL29566631

SCHEMBL29566631

CC(C)c1ccccc1-c1cc(Oc2cc(C3CCN(C)CC3)ccc2Cl)nc(NS(=O)(=O)c2cccc(N)c2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.38
▸ HTR1A P08908 9/20 0.36
▸ HTR7 P34969 9/20 0.36
▸ ALK Q9UM73 4/20 0.35
▸ DRD2 P14416 3/20 0.35
▸ HTR6 P50406 3/20 0.35
▸ HTR2A P28223 2/20 0.34
▸ ADRA1D P25100 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ ADRA1B P35368 1/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ HTR1D P28221 1/20 0.33
▸ HTR1B P28222 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ HTR1E P28566 1/20 0.33
▸ HTR2B P41595 1/20 0.33
▸ HTR3A P46098 1/20 0.33
▸ HTR5A P47898 1/20 0.33
▸ INSR P06213 1/20 0.33
▸ IGF1R P08069 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26806663 1.00 EGFR (0.38) EGFRHTR1AHTR7ALKDRD2
SCHEMBL24310487 0.94 EGFR (0.36) EGFRHTR1AHTR7ALKDRD2
SCHEMBL29566648 0.94 EGFR (0.36) EGFRHTR1AHTR7ALKDRD2
SCHEMBL29566737 0.89 HTR1A (0.35) HTR1AHTR7ALKDRD2HTR6
SCHEMBL24309248 0.89 HTR1A (0.35) HTR1AHTR7ALKDRD2HTR6
SCHEMBL29566441 0.88 HTR1A (0.38) HTR1AHTR7ALKDRD2HTR6
SCHEMBL24309259 0.88 HTR1A (0.38) HTR1AHTR7ALKDRD2HTR6
SCHEMBL24310456 0.88 HTR1A (0.39) EGFRHTR1AHTR7HTR6HTR2A
SCHEMBL29566903 0.88 HTR1A (0.39) EGFRHTR1AHTR7HTR6HTR2A
SCHEMBL24309747 0.87 HTR1A (0.37) HTR1AHTR7ALKDRD2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback